In-vivo mouse CML models using RITA in combination with CPI-203 (BET family inhibitor) showed decreased levels of CD11b, CD19, CD33, CD34 and CD45, suggesting reduced LSC engraftment [219,222]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.